Jun 2026 (Q2 FY26) — Aug 4, 2026
Henry Schein Q2 FY26 — Strong Sales and Margin Expansion Drive Raised Full-Year Guidance
Read the full callHenry Schein (HSIC) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Henry Schein earnings: last reported Tue, 4 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 3,458 | +6.7% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 5.0 | +0.3 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 94.0 | +9.3% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$83.97 −2.79% · −$2.41
Performance +33.3% 1Y
1Y: $62.98 on 17 Oct 2025 → $83.97. High $90.86 (3 Sept 2026), low $62.32 (29 Oct 2025).
- Previous close
- $86.38
- 52-week range
- $62.32 – $90.86
- One year
- +31.35%
Overview
- Symbol
- HSIC
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Mar 2026 (Q1 FY26) — May 5, 2026
Henry Schein Q1 FY26 — Strong Start with Market Share Gains and Margin Expansion
Read the full callDec 2025 (Q4 FY25) — Feb 24, 2026
Henry Schein Q4 FY25 — Strong Sales Growth and Strategic Execution
Read the full callEvery analysed call
Henry Schein earnings calls (HSIC)
Financials
What the filings say
Net profit, year on year: +9% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 3,174 | 3,191 | 3,168 | 3,240 | 3,339 | 3,437 | 3,368 | 3,458 |
| Operating profit | 157 | 155 | 175 | 151 | 164 | 163 | 182 | 171 |
| Operating margin | 5.0% | 4.9% | 5.5% | 4.7% | 4.9% | 4.7% | 5.4% | 5.0% |
| Interest | 34 | 35 | 35 | 38 | 38 | 39 | 39 | 43 |
| Profit before tax | 128 | 126 | 145 | 121 | 134 | 133 | 150 | 137 |
| Tax rate | 25.0% | 24.6% | 24.1% | 25.6% | 20.9% | 24.1% | 25.3% | 24.8% |
| Net profit | 99 | 94 | 110 | 86 | 101 | 101 | 107 | 94 |
| EPS ($ per share) | 0.79 | — | 0.89 | 0.71 | 0.84 | — | 0.93 | 0.83 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Reserves | 3,209 | 3,116 | 3,455 | 3,595 | 3,678 | 3,860 | 3,771 | 3,293 |
| Total liabilities | 4,647 | 3,234 | 3,460 | 3,805 | 3,936 | 5,420 | 5,381 | 6,421 |
| Fixed assets | 314 | 330 | 342 | 366 | 383 | 498 | 531 | 621 |
| Total assets | 8,501 | 7,151 | 7,773 | 8,481 | 8,607 | 10,573 | 10,218 | 11,215 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 685 | 654 | 599 | 710 | 602 | 500 | 848 | 712 |
| Cash from investing | -193 | -424 | -115 | -677 | -276 | -1,135 | -430 | -400 |
| Cash from financing | -604 | -216 | -187 | -333 | -315 | 701 | -510 | -188 |
| Net cash flow | -94 | 26 | 315 | -303 | -1 | 54 | -49 | 34 |
| Capital expenditure | -71 | -76 | -49 | -79 | -96 | -147 | -148 | -139 |
| Free cash flow | 613 | 578 | 550 | 631 | 506 | 353 | 700 | 573 |
HSIC revenue by segment
| Segment | Q2 FY2024 | Q3 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|---|---|
| Global Distribution and Value Added Services | — | — | 84% | 84% | 85% | 84% | 84% | 84% | +6.5% |
| Global Specialty Products | — | — | 11% | 11% | 10% | 11% | 11% | 11% | +7.5% |
| Global Technology | — | — | 5% | 5% | 5% | 5% | 5% | 5% | +8.4% |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
HSIC operating KPIs by quarter
| KPI | Dec 2025 Q4 FY25 | Mar 2026 Q1 FY26 | Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|---|
| Dentrix Ascend and Dentally subscribers | 11K+And now we have more than 11,000 Dentrix Ascend and Dentally subscribers, of course, the largest installed base in the world.Source: earnings call transcript | 13K+The number of cloud-based customers increased by roughly 25% year-over-year, primarily from new accounts, and we now have more than 13,000 Dentrix Ascend and Dentale subscribers.Source: earnings call transcript | <13KAlmost 13,000 customers now subscribe to our Dentrix Ascend and Dentale cloud-based platforms, and we're seeing more customers move toward our higher-featured packages, which is increasing our monthly revenue per customer.Source: earnings call transcript | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Revenue by region
Q3 FY2024 · share of revenue
- North America 74% ↑ 2 pt
- International 26% ↓ 1 pt
As HSIC cuts its regions in its filings; they can nest, so they need not add to 100%.
Insider filings
72 filings between Nov 13, 2025 and Sep 8, 2026.
Open market
decisions to buy or sellPurchases
$691.9K
1 purchase by 1 insider
Sales
$8.58M
10 sales by 5 insiders
Compensation
not trading decisions- 22
- Award — granted as compensation
- 16
- Tax withheld — shares kept back by the company to cover tax
Also filed: 14 gifts, 8 dispositions to the issuer, 1 other.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| BERGMAN STANLEY M | — | $7.54M | Mar 2, 2026 |
| DANIEL WILLIAM K | $691.9K | — | May 11, 2026 |
| MLOTEK MARK E | — | $478.7K | Mar 4, 2026 |
| LASKAWY PHILIP A | — | $228.5K | Mar 5, 2026 |
| KUEHN KURT P | — | $224.6K | Mar 10, 2026 |
| Popeck Thomas C | — | $98.6K | Mar 19, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 8, 2026 | Albertini Andrea CEO, Global Dist. & Tech. | Tax withheld | 603 | $53.6K |
| Sep 8, 2026 | Albertini Andrea CEO, Global Dist. & Tech. | Disposition to issuer | 3,984 | $0 |
| Jun 12, 2026 | DANIEL WILLIAM K Director | Award | 2,215 | $0 |
| May 26, 2026 | BERGMAN STANLEY M Insider | Gift | 50 | $0 |
| May 21, 2026 | BERGMAN STANLEY M Director | Gift | 50 | $0 |
| May 19, 2026 | BERGMAN STANLEY M Director | Gift | 1,040 | $0 |
| May 11, 2026 | DANIEL WILLIAM K Director | Purchase | 10,000 | $691.9K |
| Mar 19, 2026 | Popeck Thomas C CEO, Henry Schein Products | Sale | 1,355 | $98.6K |
| Mar 17, 2026 | Ettinger Michael S EVP & Chief Operating Officer | Gift | 1,000 | $0 |
| Mar 16, 2026 | Albertini Andrea CEO, Global Dist. & Tech. | Tax withheld | 1,401 | $104.5K |
| Mar 16, 2026 | South Ronald N. SVP & Chief Financial Officer | Tax withheld | 5,216 | $389.2K |
| Mar 16, 2026 | Ettinger Michael S EVP & Chief Operating Officer | Tax withheld | 4,214 | $314.4K |
| Mar 16, 2026 | BERGMAN STANLEY M Director | Gift | 400 | $0 |
| Mar 16, 2026 | Popeck Thomas C CEO, Henry Schein Products | Tax withheld | 587 | $43.8K |
| Mar 16, 2026 | Ettinger Michael S EVP & Chief Operating Officer | Gift | 1,300 | $0 |
| Mar 16, 2026 | Sheehy Christine Zayac SVP, Chief Human Res. Officer | Tax withheld | 463 | $34.5K |
| Mar 16, 2026 | MLOTEK MARK E EVP, Chief Strategic Officer | Tax withheld | 5,928 | $442.3K |
| Mar 16, 2026 | BERGMAN STANLEY M Director | Tax withheld | 50 | $3.7K |
| Mar 12, 2026 | BERGMAN STANLEY M Director | Gift | 970 | $0 |
| Mar 10, 2026 | KUEHN KURT P Director | Sale | 2,844 | $224.6K |
| Mar 6, 2026 | MLOTEK MARK E EVP, Chief Strategic Officer | Gift | 300 | $0 |
| Mar 6, 2026 | Sheehy Christine Zayac SVP, Chief Human Res. Officer | Award | 7,087 | $0 |
| Mar 6, 2026 | Popeck Thomas C CEO, Henry Schein Products | Award | 53,206 | $0 |
| Mar 6, 2026 | Albertini Andrea CEO, Global Dist. & Tech. | Award | 60,631 | $0 |
| Mar 6, 2026 | South Ronald N. SVP & Chief Financial Officer | Award | 20,296 | $0 |
| Mar 6, 2026 | Lowery Frederick M. CEO | Award | 64,433 | $0 |
| Mar 6, 2026 | Ettinger Michael S EVP & Chief Operating Officer | Award | 27,061 | $0 |
| Mar 6, 2026 | MLOTEK MARK E EVP, Chief Strategic Officer | Award | 27,061 | $0 |
| Mar 6, 2026 | DANIEL WILLIAM K Director | Award | 2,577 | $0 |
| Mar 6, 2026 | SHEARES BRADLEY T Director | Award | 2,577 | $0 |
| Mar 6, 2026 | LASKAWY PHILIP A Director | Award | 2,577 | $0 |
| Mar 6, 2026 | BERGMAN STANLEY M Director | Award | 2,577 | $0 |
| Mar 6, 2026 | Serota Scott Philip Director | Award | 2,577 | $0 |
| Mar 6, 2026 | HERRING JOSEPH L Director | Award | 2,577 | $0 |
| Mar 6, 2026 | BERGMAN STANLEY M Director | Other | 3,812 | $0 |
| Mar 6, 2026 | Faig Carole T Director | Award | 2,577 | $0 |
| Mar 6, 2026 | Margulies Anne H. Director | Award | 2,577 | $0 |
| Mar 6, 2026 | ALI MOHAMAD Director | Award | 2,577 | $0 |
| Mar 6, 2026 | Tuckson Reed Vaughn Director | Award | 2,577 | $0 |
| Mar 6, 2026 | HOMBACH ROBERT J. Director | Award | 2,577 | $0 |
| Mar 6, 2026 | KUEHN KURT P Director | Award | 2,577 | $0 |
| Mar 6, 2026 | DERBY DEBORAH Director | Award | 2,577 | $0 |
| Mar 6, 2026 | MLOTEK MARK E EVP, Chief Strategic Officer | Gift | 300 | $0 |
| Mar 5, 2026 | MLOTEK MARK E EVP, Chief Strategic Officer | Gift | 1,215 | $0 |
| Mar 5, 2026 | LASKAWY PHILIP A Director | Sale | 2,844 | $228.5K |
| Mar 4, 2026 | MLOTEK MARK E EVP, Chief Strategic Officer | Sale | 1,825 | $147.5K |
| Mar 4, 2026 | MLOTEK MARK E EVP, Chief Strategic Officer | Sale | 4,100 | $331.3K |
| Mar 2, 2026 | BERGMAN STANLEY M Chairman, CEO | Sale | 19,954 | $1.62M |
| Mar 2, 2026 | BERGMAN STANLEY M Chairman, CEO | Sale | 23,858 | $1.94M |
| Mar 2, 2026 | Lowery Frederick M. CEO | Award | 30,723 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for HENRY SCHEIN INC
Free account. Everything above stays public.
Write why you follow HENRY SCHEIN INC and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading